Aim. To determine the dynamics of cryoprecipitate production in Russian blood service institutions in comparison with such institutions in other countries.Materials and methods. Reports provided by Russian blood service institutions during the 1997–2017 period were analysed, along with European standards for blood collection and transfusion.Results. Over the 1997–2004 period, the number of cryoprecipitate units issued annually ranged from 263,897 (2000) to 297,890 (2002) units. Over the subsequent 8 years, the number of annually released cryoprecipitate decreased to 23,663 units, having reached a historical minimum in 2012. From 2012 to 2017, the number of annually issued cryoprecipitate units increased by 80.0 %, reaching the amount of 42,589 units. Reasons for such a wavelike dynamics in cryoprecipitate production in Russia have been determined. In addition, directions for expanding the use of this product in the correction of hypofibrinogenemia have been identified.Conclusion. Cryoprecipitate should be re-introduced into the practice of clinical transfusiology. To this end, national clinical guidelines for cryoprecipitate application should be developed.

No abstract

No abstract

No abstract